|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 9 July 2009, Vol. 114, No. 2, pp. 478-484. Prepublished online as a Blood First Edition Paper on May 6, 2009; DOI 10.1182/blood-2008-11-188763.
VASCULAR BIOLOGY The prototype endothelial marker PAL-E is a leukocyte trafficking molecule1 MediCity Research Laboratory and Department of Medical Microbiology, University of Turku and National Public Health Institute, Turku; 2 Turku Graduate School of Biomedical Sciences, Turku; and 3 Department of Biology, University of Turku, Turku, Finland
Pathologische Anatomie Leiden-endothelium antibody has been used for more than 20 years as a marker for vascular endothelium. Despite its widespread use, the target of this antibody was only recently identified as plasmalemma vesicle–associated protein-1 (PV-1). However, no function has been identified for this molecule. Here we report that activation of human umbilical vein endothelial cells with tumor necrosis factor-
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2009 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
resulted in a remarkable redistribution of PV-1 toward the peripheral areas of the cells. Furthermore, in vitro endpoint transmigration experiments showed that transcellularly migrating lymphocytes are surrounded by rings containing PV-1 and caveolin-1. Moreover, PV-1 associates physically with vimentin. In addition, administration of anti–PV-1 antibody during capillary flow assays resulted in a significant inhibition of lymphocyte transmigration through the endothelial cell layer, whereas rolling and adhesion were unaffected. In vivo blockage of PV-1 by an antibody in acute peritonitis and air pouch model resulted in a significant decrease in the number of migrating leukocytes. Here we thus define leukocyte transendothelial migration as the first known function for PV-1. 
